Protara Therapeutics, Inc. - Common Stock — Cash Flow (NASDAQ:TARA) | MetaTrader

Open full chart Full chart

Financials

Overview Statement Statistics

Quarterly Annual

Cash from operating activities -23.41 M-34.5 M-26.46 M-37.56 M-35.81 M-56.37 M -62.99 M Cash from investing activities 2.83 M-98.19 M14.95 M53.11 M19.16 M-139.49 M -95.86 M Cash from financing activities 189.4 M-228 K-90 K-91 K139.87 M82.72 M 82.13 M Free cash flow -23.41 M-34.5 M-26.46 M-37.56 M-35.81 M-56.37 M -62.99 M

News

Protara Therapeutics, Inc. (TARA) Discusses Interim Safety and Durability Data From STARBORN-1 Trial of TARA-002 in Lymphatic Malformations - Slideshow (NASDAQ:TARA) 2026-05-20

Protara Therapeutics, Inc. (TARA) Discusses Interim Safety and Durability Data From STARBORN-1 Trial of TARA-002 in Lymphatic Malformations Transcript

TD Cowen reiterates Protara Therapeutics stock rating on trial data

JPMorgan initiates Protera Therapeutics stock at Overweight

Protara Therapeutics, Inc. (TARA) Presents at 2026 ASCO Genitourinary Cancers Symposium - Slideshow (NASDAQ:TARA) 2026-02-26

AMD and Keysight Technologies among market cap stock movers on Tuesday

AMD, IBM among market cap stock movers on Tuesday

What's Going On With Protara Therapeutics Stock Tuesday? - Protara Therapeutics (NASDAQ:TARA)

Protara Therapeutics stock tumbles on trial data release

Protara reports interim results from bladder cancer trial

Protara to present bladder cancer treatment data at ASCO symposium

Protara Therapeutics, Inc. (TARA) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow (NASDAQ:TARA) 2026-01-15